AUG 11, 2026 · PHASE 3 TRIAL
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
ClinicalTrials.gov
This is a Phase 3 RCT still recruiting with no results posted; the registry record describes a planned non-inferiority design testing empagliflozin continuation in acute decompensated heart failure, but no efficacy or safety data are available.
Reported
Planned enrollment536
PhasePHASE 3
Primary endpoint assessment timep…Day 90